Riskpilot← Back to searchSign inGet full accessEql Pharma Int AB
ABActiveOrg 5569579484Stortorget 1Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20140 employees
Revenue 2025
SEK 3,2M
-46% vs 2024
EBITDA margin
54.8%
+13% vs 2024
Equity ratio
0.5%
Financial strength
Net profit 2025
SEK 121K
+1244% vs 2024
| Revenue | SEK 3,2M | -46% |
| EBITDA | SEK 1,8M | +13% |
| Net profit | SEK 121K | +1244% |
| Total assets | SEK 192,7M | +6382% |
| Equity | SEK 968K | +14% |
| Employees | 0 | — |
Legal name
Eql Pharma Int AB
Org number
5569579484
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
10 januari 2014
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolagets verksamhet skall vara att tillverka, utveckla, idka handel med medicinska-, diagnostiska-, farmaceutiska- och kemiska-tekniska produkter, förvärva och upplåta licenser och agenturer för sådana produkter samt därmed förenlig verksamhet. Bolaget ska även idka finansiell verksamhet, dock inte sådan verksamhet som avses i bankrörelselagen eller lagen om kreditmarknadsbolag.
Address
Stortorget 1
Email
anna.jonsson@eqlpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 9 207 | 6 007 | 4 241 | 5 197 | 3 704 | 5 580 | 6 001 | 3 219 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −107 | −81 | 2 868 | 442 | −945 | 631 | 372 | 161 | 1 561 | 1 763 |
| Depreciation & amort. | −0 | −200 | −90 | −246 | −276 | −155 | −44 | −0 | −0 | −1 611 |
| EBIT | −107 | −281 | 2 778 | 196 | −1 221 | 476 | 328 | 161 | 1 561 | 152 |
| Net financials | — | — | — | — | — | — | — | −3 | — | 1 |
| Profit before tax | −107 | −281 | 378 | 196 | −221 | 477 | 8 | 8 | 11 | 153 |
| Tax | −0 | −0 | −0 | −0 | −17 | −55 | −2 | −2 | −2 | −32 |
| Net profit | −107 | −281 | 378 | 196 | −238 | 422 | 6 | 6 | 9 | 121 |
| Item | 2015 | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 238 | 1 904 | 6 546 | 2 902 | 3 178 | 3 794 | 2 861 | 3 702 | 2 973 | 192 695 |
| Equity | 50 | 69 | 446 | 642 | 404 | 826 | 832 | 838 | 847 | 968 |
| Long-term debt | 173 | 1 455 | 5 473 | 1 703 | 1 953 | 2 407 | 1 487 | 2 226 | 1 550 | 191 215 |
| Short-term debt | 15 | 380 | 626 | 556 | 821 | 561 | 542 | 638 | 576 | 512 |
| Total debt | 188 | 1 835 | 6 099 | 2 259 | 2 774 | 2 968 | 2 029 | 2 864 | 2 126 | 191 727 |
EBITDA margin
54.8%
This company
15.8%
Market median
+247% vs market
20152025
Equity ratio
0.5%
This company
38.2%
Market median
-99% vs market
20152025
Return on equity
12.5%
This company
18.4%
Market median
+32% vs market
20152025
Net profit margin
3.8%
This company
8.1%
Market median
-53% vs market
20152025
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20152025
Debt / equity
198.07×
This company
0.62×
Market median
-31847% vs market
20152025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-04-01 – 2020-03-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-04-01 – 2019-03-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-01-01 – 2018-03-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MS Chief Auditor | Chief Auditor | 2022 | — | — |
CO Chief Auditor | Chief Auditor | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Deputy Board Member | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Eql Pharma AB | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Eql Pharma AB
Eql Pharma Int AB Board members of Eql Pharma Int AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Sofia Ekelund | Chief Auditor | 0 companies |
| Carl Olov Strömberg | Chief Auditor | 0 companies |
| Lars Christer Fredrik Fåhraeus | Board of Directors | 0 companies |
| Jennie Therese Sterning | Deputy Board Member | 0 companies |
| Anna Ellen Clara Jönsson | Deputy Board Member | 0 companies |